Design of the Dutch prevention of influenza, surveillance and management (PRISMA) study.
Rationale and design of a study on the cost-effectiveness of the Dutch influenza vaccination campaign are described. During two influenza epidemics, about 75,000 primary care patients recommended for influenza vaccination are included. Cases have fatal or non-fatal influenza, pneumonia, otitis media, acute respiratory disease (ARD), heart failure, myocardial infarction, depression or diabetes dysregulation. Per case four controls are sampled, frequency matched on age and high-risk co-morbidity (<18 years, 18-64, >/=65 healthy, >/=65 with co-morbidity). Baseline and outcome data are retrieved from patient records. During the 1999-2000 influenza A epidemic 5891 (7.9%) high-risk children, 24,848 (33.2%) high-risk adults aged 18-64 years, 18,484 (24.7%) elderly with co-morbidity and 25,527 (34.1%) healthy elderly had been included. The mortality rate was 5.2 per 1000 and 2035 non-fatal outcome events were recorded (incidence rate 27.2/1000).
Hak
E
E
Julius Center for Health Sciences and Primary Care, P.O. Box 85060, 3508 AB, Utrecht, The Netherlands. e.hak@med.uu.nl
van Loon
S
S
Buskens
E
E
van Essen
G A
GA
de Bakker
D
D
Tacken
M A J B
MA
van Hout
B A
BA
Grobbee
D E
DE
Verheij
Th J M
TJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D016001:Confidence Intervals; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000379:methods* / Q000706:statistics & numerical data; D007223:Infant; D007231:Infant, Newborn; D007252:Influenza Vaccines / Q000191:economics / Q000627:therapeutic use; D007251:Influenza, Human / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D016015:Logistic Models; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D016017:Odds Ratio; D011159:Population Surveillance / Q000379:methods*
D007252:Influenza Vaccines